BMLA 2026 conference – Brain-Gut Photobiomodulation therapy in ALS

Photobiomodulation therapy (PBMT) uses low-intensity red to near-infrared (NIR) light to stimulate, enhance and heal cell and tissue function. Over the last 24 years, Prof Chazot  has previously reported a wide range of studies that PBMT1068nm can elicit the 3Ns (neuroprotection, neuroplasticity, neurorepair) in the CNS, as well as improve cognitive function and memory performance in dementia patients and ageing individuals.

Herein, at the BMLA conference, he will report new evidence that PBMt 1068nm displays pro-autophagy, anti-inflammatory effects under cellular stress, and oxidative stress-induced cellular senescence reversal (senomorphic) effects.

Furthermore, in recent human case studies, the novel dual FDA and CE approved brain-gut CeraThrive device, showed a highly significant improvement in major symptoms in a wide range of neurological and peripheral pathologies at 3 months. In a series of ALS cases with moderate symptoms, 5 of 8 cases showed stability or improvement at 3 months. Additionally, a Bulbar form ALS test case, displayed initially stability, and then a profound improvement of 5 units in ALS symptoms (ALSFRS-R), a peripheral oxygen saturation improvement of 6% to 95%, and subjective improvements in ambulation, brain fog symptoms, spasticity, swallowing, and general wellbeing at 3 years. BMLA2026